U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Tofacitinib. [Updated 2019 Jul 20].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Tofacitinib

Revised: July 20, 2019.

CASRN: 477600-75-2



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of tofacitinib during breastfeeding. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer and an expert panel recommend that breastfeeding be discontinued during tofacitinib therapy and for 18 hours after the last dose of Xeljanz or 36 hours after the last dose of Xeljanz XR.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Rheumatoid Arthritis) Auranofin, Gold Sodium Thiomalate, Hydroxychloroquine, Infliximab, Methotrexate, Penicillamine, Sulfasalazine

References

1. Mahadevan U, Robinson C, Bernasko N et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156:1508-24. PubMed PMID: 30658060.

Substance Identification

Substance Name

Tofacitinib

CAS Registry Number

477600-75-2

Drug Class

Breast Feeding

Lactation

Antirheumatic Agents

Enzyme Inhibitors

Janus Kinase Inhibitors

Signal Transduction Inhibitors

Protein Kinase Inhibitors